Target validation

Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients.   The international alliance will focus on leveraging the complementary capabilities, platforms and technologies from both partners, to accelerate oncology pipeline assets across a range of developmental […]

CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library?  In this on-demand […]

Join DDW and Synthego for this free exclusive event today at 3pm GMT. Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Register now to hear speakers Kevin Holden and Teddy Lin, Associate Director, Commercial Strategy, Synthego. […]

The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new therapeutic targets in this underfunded specialty.  […]

In this webinar, hosted by DDW and supported by Synthego, Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Join this free exclusive event on 9 November at 3pm GMT to hear speakers Kevin Holden and […]

CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your CRISPR library? In this webinar, hosted […]

The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of […]

The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and antibodies to expedite the process of […]

Join this free exclusive event to find out more. It will take place on 9 November at 3pm GMT. CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if […]

Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward genetic screens being seen as […]

Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations with significant unmet medical needs. […]

Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated their long-term strategic drug discovery and development partnership […]

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality […]

The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet, despite the drive to fail […]

Stem Cell Differentiation By Dr Lilian Hook Stem cells are extraordinary cells, capable of both self-renewal and differentiation to mature somatic cells in vivo and in vitro (1,2). They have many features and advantages which could revolutionise drug development and healthcare applications. Stem cells offer a limitless, consistent supply of physiologically relevant cells from validated […]

Targeting Energy Metabolism for Cancer Therapeutic Discovery using Agilent Seahorse XF Technology Sponsored by Agilent This white paper discusses targeting energy metabolism for cancer therapeutic discovery using Agilent Seahorse XF technology. Abstract Altered energy metabolism is now recognized as a driver in many diseases. In cancer research, significant advances have been made in defining druggable […]